Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967898 | 0.84 | LTA4H (0.46) | GRM5RRM1MEN1KMT2AALOX5 | |
| SCHEMBL9967892 | 0.82 | GRM5 (0.47) | GRM5RRM1LMNAMEN1KMT2A | |
| SCHEMBL10477980 | 0.74 | KMT2A (0.50) | RRM1LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL1072784 | 0.74 | GRM5 (0.62) | GRM5LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL13841458 | 0.74 | GRM5 (0.62) | GRM5LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL31185833 | 0.73 | RRM1 (0.57) | RRM1LMNAMEN1KMT2AALOX5 | |
| SCHEMBL4568931 | 0.72 | KMT2A (0.54) | LMNAMEN1KMT2AALOX5 | |
| SCHEMBL30994413 | 0.72 | CYP1A2 (0.58) | GRM5LMNAMEN1KMT2AALOX5 | |
| SCHEMBL4516341 | 0.72 | CYP1A2 (0.58) | GRM5LMNAMEN1KMT2AALOX5 | |
| SCHEMBL4596162 | 0.72 | KMT2A (0.57) | LMNAMEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908841-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-03-06 | — | — | US | disclosed |
| US-20180042867-A1 | METHODS OF TREATING CANCER | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172945-A1 | METHODS OF TREATING BREAST CANCER | MITCHELL WOODS PHARMACEUTICALS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-12 | — | — | US | disclosed |
| US-9522871-B2 | Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2016-11-17 | — | — | US | disclosed |
| US-9492405-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-06-11 | — | — | US | disclosed |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | SRI INTERNATIONAL | 2013-01-03 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | GRM5 615/4885RRM1 395/4885LMNA 3712/4885 |
| US-20160009636-A9 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | GRM5 615/4885RRM1 395/4885LMNA 3712/4885 |
| US-20150157580-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | GRM5 83/4885RRM1 2961/4885LMNA 4009/4885 |
| US-20180042867-A1 | METHODS OF TREATING CANCER | GPR55, ADRB2, GRK2 | GRM5 65/4885RRM1 3003/4885LMNA 3722/4885 |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | GRM5 189/4885RRM1 1270/4885LMNA 4362/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | GRM5 615/4885RRM1 395/4885LMNA 3712/4885 |
| US-20170172945-A1 | METHODS OF TREATING BREAST CANCER | CNR2, ADRB2, CNR1 | GRM5 489/4885RRM1 3547/4885LMNA 4027/4885 |
| US-20170081276-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | GRM5 615/4885RRM1 395/4885LMNA 3712/4885 |
| US-20170172944-A1 | METHODS OF TREATING MELANOMA | CNR2, ADRB2, CNR1 | GRM5 746/4885RRM1 2973/4885LMNA 3319/4885 |
| US-20140187645-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | GRM5 615/4885RRM1 395/4885LMNA 3712/4885 |
| US-20160331702-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | GRM5 83/4885RRM1 2961/4885LMNA 4009/4885 |
| US-20170007556-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | GRM5 177/4885RRM1 1285/4885LMNA 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.